Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: A case report and review of the literature

Scandinavian Journal of Infectious Diseases

Volumn 44, Issue 3, 2012, Pages 228-230

  El Herte, Rima I ^a   Baban, Tania A ^a   Kanj, Souha S ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Abdominal infections; Clostridium difficile resistance; Refractory colitis; Rifaximin; Tigecycline

Indexed keywords

METRONIDAZOLE; RIFAXIMIN; TIGECYCLINE; VANCOMYCIN;

AGED; ANAMNESIS; CASE REPORT; CLOSTRIDIUM DIFFICILE INFECTION; DRUG TREATMENT FAILURE; FEMALE; HUMAN; PHYSICAL EXAMINATION; RECURRENT DISEASE; REVIEW; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; METRONIDAZOLE; MINOCYCLINE; RECURRENCE; RIFAMYCINS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84857590552     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2011.616224     Document Type: Review

References (14)

1. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55.
2. Hawser SP. Activity of tigecycline against recent European clinical isolates of Clostridium difficile. Int J Antimicrob 2010;35:97-8.
3. Nore T, Alriksson I, Kerlund TA, Burman LG, Unemo M. In vitro susceptibility to 17 antimicrobials of clinical Clostridium difficile isolates collected in 1993-2007 in Sweden. Clin Microbiol Infect 2010;16:1104-10.
4. Nord CE, Sillerström E, Wahlund E. Effect of tigecycline on normal oropharyngeal and intestinal microfl ora. Antimicrob Agents Chemother 2006;50:3375-80. (Pubitemid 44527513)
5. Jump RL, Li Y, Pultz MJ, Kypriotakis G, Donskey CJ. Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production. Antimicrob Agents Chemother 2011;55:546-9.
6. Wilcox MH. Evidence for low risk of Clostridium difficile infection associated with tigecycline. Clin Microbiol Infect 2007;13:949-2.
7. Cheong EY, Gottlieb T. Intravenous tigecycline in the treatment of severe recurrent Clostridium difficile colitis. Med J Aust 2011;194:374-5.
8. Herpers BL, Vlaminckx B, Burkhardt O, Blom H, Biemond-Moeniralam HS, Hornef M, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009;48: 1732-5.
9. Lu CL, Liu CY, Liao CH, Huang YT, Wang HP, Hsueh PR. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole. Int J Antimicrob Agents 2010;35:311-2.
10. Kopterides P, Papageorgiou C, Antoniadou A, Papadomichelakis E, Tsangaris I, Dimopoulou I, Armaganidis A. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth Intensive Care 2010;38:755-8.
11. Neff G, Zacharias V, Kaiser TE, Gaddis A, Kemmer N. Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: a case series. Liver Transpl 2010;16:960-3.
12. J ohnson S, Schriever C, Galang M, Kelly CP, Gerding DN. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007;44:846-8. (Pubitemid 46365312)
13. Johnson S, Schriever C, Patel U, Patel T, Hecht D, Gerding DN. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009;15:290-1.
14. Berman AL. Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2007;41: 932-3. (Pubitemid 350307082)